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Foxp3+ T regulatory (Treg) cells control all aspects of the immune response. Here, I will review the in vitro
model systems that have been developed to define the mechanisms used by Treg cells to suppress a large
number of distinct target cell types. These mechanisms can be broadly divided into those that target T cells
(suppressor cytokines, IL-2 consumption, cytolysis) and those that primarily target antigen-presenting cells
(decreased costimulation or decreased antigen presentation). Although multiple mechanisms for Treg cell
suppression have been shown in vitro, it is unclear whether the same or different mechanisms are used by
Treg cells in vivo. An increase in our understanding of Treg cell suppressor mechanisms will offer an insight
into how Treg cell function can be manipulated either positively or negatively in vivo.Introduction
The fieldof T regulatory (Treg) or T suppressor cellswas rebornby
the observations of Sakaguchi et al. (1995) that depletion of the
minor population of CD4+ T cells that coexpress CD25 from
a population of normal adult CD4+ T cells generated a population
of cells that induced a spectrum of autoimmune diseases when
transferred to an immunocompromised recipient. Cotransfer of
the CD25+ cells prevented the development of autoimmunity.
The critical question that needs to be addressed is the mecha-
nism of action of these Treg cells in vivo. It was thought that the
development of an in vitromodel system (Thornton and Shevach,
1998; Takahashi et al., 1998) for the analysis of Treg cell function
would offer major insights into the mechanism of action of Treg
cells in vivo. However, the in vitro model systems have identified
a long list ofmolecules andprocesses that contribute to Tregcell-
suppressive activities and it remains unclear whether any of the
conclusions drawn from these studies shed light on how Treg
cells function in vivo. A detailed analysis of Treg cell function is
further confounded by the large number of different cell types
that are purported to be directly targeted by Foxp3+ Treg cell
(Box 1). Althoughmultiple T cell subsets (e.g., Tr1 cells, Th3 cells,
Th1 and Th2 cells, etc.) can certainly exert negative immunoreg-
ulatory effects by producing immunomodulatory cytokines
(IL-10, TGF-b), I will confine this discussion to CD4+Foxp3+
Treg cells that develop in both the thymus and periphery and
represent the major Treg cell populations that are critical for
immune homeostasis.
Lessons to Be Learned from In Vitro Suppression
Assays: Responder T Cells as Targets
Box 2 summarizes some of the major conclusions drawn from
the in vitro suppression assays performed with both human
andmouse Foxp3+ Treg cells that are agreed to bymost workers
in the field. Numerous controversial issues remain regarding the
interpretation of these assays and I will discuss several of the
ones that I regard asmost critical. First, what is the cellular target
for Treg cell-mediated suppression in vitro? Suppression assays
are performed in two distinct ways. In some studies, a source of
antigen-presenting cells (APCs,most often irradiated T-depleted636 Immunity 30, May 22, 2009 ª2009 Elsevier Inc.spleen cells or unirradiated dendritic cells [DCs]) is added and
the stimulus for activation is soluble anti-CD3, whereas in other
studies bead-coupled or plate- bound antibodies together with
anti-CD28 are used in the complete absence of APCs. In the
former case, the target of Treg cell suppression can be the
APC, the responder cells, or both, whereas in the latter situation
the responder T cells are the only targets. This section will focus
on potential mechanisms of suppression that target responder
T cells (Figure 1), whereas the next section will deal with mech-
anisms that potentially target APCs. As is apparent from the
discussion to follow, this division is somewhat arbitrary and
some mechanisms can target both cell types.
Murine Treg cells are potent suppressors of T cell proliferation
in the presence of soluble anti-CD3 and APCs and are very inef-
ficient suppressors (requiring a high ratio of suppressors to
responders) when anti-CD3 is coupled to a solid phase in the
presence or absence of anti-CD28. Furthermore, in the presence
of anti-CD28 and soluble anti-CD3, suppression was frequently
abrogated secondary to induction of high amounts of IL-2
production by the responder cells (Thornton and Shevach,
1998, 2000; Thornton et al., 2004b). These results raised the
possibility that the APC is the primary target of the Treg cells,
but suppression of the response of transgenic CD8+ T cells to
stimulation with MHC class I peptide tetramers by preactivated
Treg cells was readily observed in the absence of a source of
professional APC, suggesting that Treg cells could also effi-
ciently target responder T cells (Piccirillo and Shevach, 2002).
Many studies of human Treg cell function have used bead-
coupled reagents as the stimulus in cocultures and again
substantial suppression was observed only at high suppressor
to responder ratios. It is unclear which assay system should be
used, but it is obvious that the two assays may be measuring
different components of Treg cell-suppressor function. This
issue is most relevant in interpreting studies claiming abnormal
Treg cell function in patients with autoimmune diseases, where
several studies have concluded that there is a fundamental
defect in Treg cell function based on the results obtained in
a particular in vitro assay system. An additional caveat in the
analysis of many of the results measuring human Treg cell
Box 2. Properties of Foxp3+ Treg Cell In Vitro
Box 1. Cellular Targets of Foxp3+ Treg Cell-Mediated Suppressor
Function
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with anti-CD25-coupled magnetic beads rather than CD25hi
cells purified by cell sorting. These studies did not control for
the percentage of Foxp3+ T cells in their preparations and the
bead-purified cell populations were frequently contaminated
with CD25+Foxp3 activated effector cells. When the suppres-
sion assays are performed with high concentrations of bead-
coupled reagents, suppression is incomplete and upon stimula-
tion in culture, the activated CD25+Foxp3 T effector cells can
respond to IL-2 produced by the responder cells, rapidly divide,
and deplete IL-2 from the culture, so that marked suppression of
responder T cell proliferation is observed when the cultures are
assayed after 4–5 days.
Most studies have demonstrated that Treg cells mediate
suppression by inhibiting the induction of IL-2 mRNA (and
mRNA for other effector cytokines) in the responder Foxp3
T cells (Thornton and Shevach, 1998; Takahashi et al., 1998;
Oberle et al., 2007). Furthermore, the addition of exogenous IL-2
had no effect on the Treg cell-mediated suppression of IL-2
mRNA production (Thornton et al., 2004a; Oberle et al., 2007).
The role of IL-2 consumption in the suppressive mechanism of
Treg cells is under dispute. Treg cells express all three compo-
nents of the high-affinity IL-2R—CD25, CD122, and CD132—
and IL-2 is essential not only for Treg cell homeostasis in vivo
(Yu et al., 2009), but also for their efficient suppressor function
in vitro (Thornton et al., 2004a). One study (Pandiyan et al.,
2007) has raised the possibility that Treg cells may compete
with Foxp3 T cells for IL-2, consume it, and inhibit the prolifer-
ation of Foxp3 T cells, resulting in a form of apoptosis depen-
dent on the proapoptotic factor Bim. Curiously, this study is
the only one to claim that Treg cells do not inhibit IL-2 production
by responder T cells. Although it has been widely assumed that
Foxp3+ Treg cells express high numbers of high-affinity IL-2
receptors that would render them efficient competitors, quanti-
tation of the number of high-affinity IL-2 receptors on Foxp3+
T cells has never been determined and is dependent not on the
expresssion of CD25, the low-affinity IL-2 receptor, but on theexpressions of CD122 and CD132 that are required to form
the high-affinity IL-2 receptor complex. In a hybrid system where
human Treg cells were shown to be capable of efficiently sup-
pressing the proliferation of mouse responder cells, the addition
of antihuman CD25 that blocks IL-2 binding also had no effect on
the function of the human Treg cells (Tran et al., 2009a). Taken
together, these studies argue against IL-2 consumption as
a major pathway of Treg cell suppression in vitro, but IL-2
consumption may influence the results of suppression assays
when activated conventional T cells contaminate Treg cells
used in the assays.
Could a soluble suppressor cytokine mediate Treg cell
suppressor function in vitro? It should be emphasized that the
failure to observe suppression when Treg cells are separated
from the responder cells by a membrane does not rule out the
possibility that Treg cells secrete an as yet uncharacterized cyto-
kine that functions in a gradient fashion and requires proximity
between suppressor and responder. It is also possible that the
production of a suppressor cytokine by either the Foxp3+ Treg
cell or by the responder cell might require cell contact between
the Treg and the responder T cell. One such candidate is IL-35,
a new inhibitory cytokine, which may contribute substantially to
the function of Treg cells by directly acting on responder T cells
(Collison et al., 2007). IL-35 is a member of the IL-12 heterodi-
meric cytokine family and constitutes a pairing between
Epstein-Barr virus-induced gene 3 (Ebi3, which normally pairs
with p28 to form IL-27) and Il12a (also known as p35 andImmunity 30, May 22, 2009 ª2009 Elsevier Inc. 637
Figure 1. Major Mechanisms byWhich Treg
Cells Can Directly Suppress Responder
Foxp3 T Cells
Treg cells may secrete suppressor cytokines that
can directly inhibit the function of responder
T cells and myeloid cells. Treg cells express high
CD25, the IL-2 receptor a chain, and have the
capacity to compete with effector T cells for IL-2
resulting in cytokine-mediated deprivation of the
effector cells and Bim-mediated apoptosis. Acti-
vated Foxp3+ Treg cells may function as cytotoxic
cells and directly kill effector cells in a manner
similar to CD8+ cytotoxic cells. Activated Treg
cells may express known (e.g., galectin-1) or
unknown molecules on their cell surface that can
interact with receptors on effector T cells resulting
in cell cycle arrest.
All of these mechanisms may also be utilized by
Treg cells to inhibit the function of antigen-pre-
senting cells or other cells of the innate immune
system.
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express both Ebi3 and Il12a. Ebi3 is a Foxp3 target gene as
shown by the fact that conditional ablation of Foxp3 in mature
peripheral Treg cells resulted in the downregulation of Ebi3
expression. Both Ebi3 and Il12a mRNA are upregulated in Treg
cells that are actively suppressing effector cells, raising the
possibility that cell contact between suppressor and responder
is required for maximal IL-35 production. Importantly, both
Ebi3/ and Il12a/ Treg cells have substantially reduced regu-
latory activity in vitro when T responder cells are stimulated with
bead-coupled anti-CD3 and anti-CD28, but the Ebi3/ and
Il12a/ Treg cells have not been tested in an in vitro system
where DCs are used as stimulators. Treg cells from Ebi3/
and Il12a/ animals also were unable to control homeostatic
proliferation and cure inflammatory bowel disease (IBD) in vivo.
Neutralizing antibodies to IL-35 are not available and the nature
of its receptor or its cellular distribution remains unknown. In
contrast to the results reported for mouse IL-35, Bardel et al.
(2008) demonstrate that Ebi3 is expressed in human plancental
trophoblasts and activated DCs, but is undetectable in normal
resting CD3+ T cells, or resting or activated Treg cells, whereas
human p35 is constitutively expressed at low amounts in many
cell types. It is therefore unlikely that human Treg cells are able
to express substantial amounts of the two Ebi3-associated het-
erodimeric cytokines, IL-35 or IL-27. Stimulation of human
Foxp3 T cells with anti-CD3 and anti-CD28 does induce Ebi3
expression and activated human Foxp3 T cells can express
p35 transcripts, indicating that activated human T cells may
produce IL-35, but coassociation of the two chains was not
observed in immunoprecipitation studies. Further analysis of
the contribution of IL-35 to Treg cell function will require the
development of neutralizing antibodies and characterization of
its receptor.
Another secreted molecule that potentially may play a role in
Treg cell-DC or Treg cell-T cell interactions is galectin-1,
a member of a highly conserved family of b-galactoside binding
proteins (Garin et al., 2007). Galectin-1 is secreted as a homo-
dimer, and binds to many glycoproteins including CD45, CD43,638 Immunity 30, May 22, 2009 ª2009 Elsevier Inc.and CD7. The consequences of galectin binding correlate with
those induced by Treg cells in responder cells including cell
cycle arrest and apoptosis and inhibition of the production of
proinflammatory cytokines. It is not clear whether galectin-1
acts as a soluble cytokine or mediates it effects via cell-cell
contact. Galectin-1 is preferentially expressed in Treg cells and
is upregulated upon T cell receptor (TCR) activation. Blocking
of galectin-1 markedly reduced the inhibitory effects of human
and mouse Treg cells and Treg cells from galectin-1-deficient
mice had reduced Treg cell activity. Another member of the
galectin family, Galectin-10, was identified by a proteomics
approach as being selectively expressed by human Treg cells
(Kubach et al., 2007). Galectin-10 is exclusively expressed
intracellularly and is probably not directly involved in the
contact-dependent suppression mediated by Treg cells.
However, galectin-10-specific siRNA treatment reversed the
anergic state of human Treg cell in vitro resulting in increased
proliferation upon activation and a partial abrogation of their
suppressive activity. The intracellular ligands for galectin-10
have not been identified.
One other potential mechanism for Treg-mediated suppres-
sion of responder T cells would be cytolysis of target cells.
Human CD4+CD25+Foxp3+ Treg cells can be activated by
a combination of antibodies to CD3 and CD46 to express gran-
zyme A and kill activated CD4+ and CD8+ T cells and other cell
types in a perforin-dependent, Fas-FasL-independent manner
(Grossman et al., 2004). Activation of mouse Treg cells also
results in upregulation of granzyme B expression and one report
has claimed that Treg cells kill responder cells by a perforin-inde-
pendent, granzyme B-dependent mechanisms (Gondek et al.,
2005) and that granzyme B-deficient Treg cells had reduced
suppressive activity in vitro. Other studies have failed to confirm
responder cells lysis by activated murine Treg cells, but demon-
strated that highly activated Treg cells could kill antigen-present-
ing, but not bystander B, cells (Zhao et al., 2006). It has been diffi-
cult to demonstrate granzyme B expression by Treg cells in vivo,
but Cao et al. (2007) demonstrate that 5%–30% of Treg cells in
a tumor microenvironment express granzyme B and these Treg
Figure 2. Major Mechanisms by which Treg
Cells Can Suppress the Function of APC
and Indirectly Block the Activation of
Foxp3 T Cells
CTLA-4 on the surface of Treg cells downregulates
or prevents the upregulation of CD80 and CD86,
the major costimulatory molecules on antigen-
presenting cells. Similarly, LAG-3 on Treg cells
can interact with MHC class II on antigen-present-
ing cells, and binding of LAG-3 to MHC class II
molecules expressed by immature DCs results in
an inhibitory signal that suppresses DCmaturation
and immunostimulatory capacity. Extracellular
ATP functions as an indicator of tissue destruction
and exerts inflammatory effects on DCs. Catalytic
inactivation of extracellular ATP by CD39 repre-
sents an anti-inflammatory mechanism that may
be used by Treg cells to prevent the deleterious
effects of ATP on antigen-presenting cell function.
In contrast, Nrp-1 promotes long interactions
between Treg cells and immature DCs and
restricts access of the effector cells to antigen-
presenting cells. Some of these mechanisms
may also be used by Treg cells to suppress
responder T cells.
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forin-dependent manner. Thus, Treg cells in certain contexts
can differentiate to become what was once termed ‘‘cytotoxic-
suppressor’’ cells. Although killing of APCs in vivo represents
a potentially potent mechanism by which Treg cells can control
both primary and secondary immune responses, no studies to
date have been able to document Treg cell-mediated cytolysis
of DC or B cells in an in vivo model.
Lessons to Be Learned from In Vitro Suppression
Assays: APC as Targets
One of themajor effects of Treg cells both in vitro and in vivo is to
inhibit the priming and differentiation of effector T cells, so the
APC is an obvious target. A number of mechanisms for Treg
cell-mediated suppression in vitro have been proposed that
appear to primarily affect the function of APC (Figure 2). The
observation that Treg cells are the only lymphocyte subpopula-
tion that constitutively expresses CTLA-4 together with the
profile of Treg cell suppression in vitro (hypoproliferation, low
cytokine production by responder cells) that closely resembles
that seen in the presence of reagents that block costimulation
have raised the possibility that the interaction of CTLA-4 on
Treg cells with CD80 and CD86 on DCs is an important pathway
by which Treg cells could mediate their suppressive functions
in vitro. A number of early studies demonstrated that Treg cells
could downregulate the expression of costimulatory molecules
on both human and mouse DC in vitro (Misra et al., 2004; Serra
et al., 2003). It was also claimed that Treg cell-mediated
suppression of proliferation could be reversed by anti-CTLA-4
or its Fab fragment in vitro, but the inhibitory effects of anti-
CTLA-4 were not seen in all studies (Thornton et al., 2004b).
Very few studies have examined the effects of anti-CTLA-4
in vivo, but it has been shown that treatment of mice with anti-
CTLA-4 abrogates suppression of IBD mediated by Treg cells
(Read et al., 2006).
The function of CTLA-4 on Treg cells has been somewhat clar-
ified by the recent demonstration that animals with a selective
deletion of expression of CTLA-4 develop systemic autoimmu-nity at 7 weeks of age (Wing et al., 2008). Thus, CTLA-4 defi-
ciency in Treg cells alone is sufficient to cause fatal disease,
and maintenance of its expression in activated effector T cells
is insufficient to prevent this outcome. Selective CTLA-4 defi-
ciency does not alter the development or homeostasis of Treg
cells or render them pathogenic. These cells remain anergic,
but are less suppressive in vitro than are their wild-type counter-
parts when DCs were used as stimulator cells. CTLA-4-deficient
Treg cells are less suppressive in vivo as indicated by the fact
that immunodeficient mice reconstituted with total CD4+
T cells from these mice show enhanced immune responses to
transplanted tumors. It has been proposed that the interaction
of CTLA-4 on Treg cells with its ligands, CD80 and CD86, on
DCs blocks the subsequent increase of CD80 and CD86 expres-
sion or even downregulates CD80 and CD86 expression induced
by antigen-specific effector cells (Onishi et al., 2008). Treg cells
from mice lacking CTLA-4 are defective when compared to
Treg cells from wild-type mice in preventing increased expres-
sion of CD80 and CD86 in DCs, and the addition of anti-CTLA-4
Fab fragments into cultures of wild-type Treg cells and DCs
partially inhibited the suppression of CD80 and CD86 expression
(Wing et al., 2008). The conclusions drawn from these studies are
that inhibition of CD80 and CD86 expression by Treg cells limits
the capacity of the DCs to stimulate naive T cells through CD28
resulting in immune suppression. The biochemical nature of the
extrinsic signal transduced to the DCs by the interaction of
CTLA-4 with CD80 and CD86 remains to be characterized.
One mechanism that may mediate the downregulation of CD80
and CD86 expression is trogocytosis, a process in which
lymphocytes extract surface molecules through the immunolog-
ical synapse from the antigen-presenting cells to which they are
conjugated (Joly and Hudriser, 2003; Qureshi et al., 2008). It is
also possible that CTLA-4 on Treg cells may interact with
CD80 and CD86 that are expressed on activated Foxp3
T cells and in some manner downregulate effector T cell func-
tions (Paust and Cantor, 2005).
A number of other mechanisms have been proposed by which
Treg cells either abrogate the antigen-presenting activity of DCsImmunity 30, May 22, 2009 ª2009 Elsevier Inc. 639
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population. Treg cells can condition DCs through a mechanism
dependent on interactions between CTLA-4 and CD80 and
CD86 to express indoleamine 2,3-dioxygenase (IDO), which is
a potent regulatory molecule that induces the catabolism of tryp-
tophan into proapoptotic metabolites that result in the suppres-
sion of activation of effector T cells. IDO induction was found to
depend on high expression of CTLA-4 on the Treg cells (Groh-
mann et al., 2002). However, there is no clear evidence of the
involvement of IDO in Treg cell function in vivo or in vitro. One
other cell surface antigen that may play a role in Treg cell
suppression of DC function is LAG-3 (CD223), a CD4 homolog
that binds MHC class II molecules with very high affinity. Binding
of LAG-3 to MHC class II molecules expressed by immature DCs
induces an ITAM-mediated inhibitory signal that suppresses DC
maturation and immunostimulatory capacity (Liang et al., 2008).
Because activated human T cells can expressMHC class II, Treg
cell-mediated ligation of LAG-3 on effectors might also result in
suppression.
In the immune system, extracellular ATP functions as an indi-
cator of tissue destruction and may exert its effects on DCs. The
intracellular ATP concentration is high so that substantial
amounts of the nucleotide are released upon cell damage. The
presence of extracellular ATP can be sensed by purinergic P2
receptors. CD39 is the dominant ectoenzyme in the immune
system that hydrolyzes ATP or ADP to AMP and is expressed
by B cells, DCs, all mouse Treg cells, and about 50% of human
Treg cells (Borsellino et al., 2007). Thus, catalytic inactivation of
extracellular ATP by CD39 is another anti-inflammatory mecha-
nism that may be used by Treg cells. Retroviral transduction of
CD25 mouse T cells with Foxp3 induced the expression of
CD39. Freshly isolated Treg cells do not hydrolyze ATP, but acti-
vated Treg cells can mediate active hydrolysis. ATP can upregu-
late CD86 expression on DCs. Pre-exposure of Treg cells to ATP
containing medium reduced ATP-driven DC maturation.
Removal of extracellular ATP by CD39 may allow the Treg cell
to enter inflamed regions and permit the Treg cell to quench
ATP-driven proinflammatory processes on multiple cell types,
particularly DCs. CD39-deficient Treg cells are dysfunctional
because they are not anergic and proliferate in response to
anti-CD3 and anti-CD28 stimulation in the absence of exoge-
nous IL-2. CD39-deficient cells are also about 50% less effective
at suppressing stimulation of T cells from A2A-deficient mice
when compared with the ability of WT T cells to suppress WT
T cell proliferation. The immunomodulatory effects of removal
of ATP byCD39 can be amplified by the generation of adenosine.
Adenosine can be generated by CD39 in concert with the 50-
ecto-nucleoside CD73, which dephosphorylates the CD39
product, AMP (Deaglio et al., 2007). Adenosine signals via the
A2A adenosine receptor and may inhibit the functions of DCs
as well as act directly on activated T cells.
One other molecule that is secreted by Treg cell and that may
affect DC function is fibrinogen-like protein 2 (FGL2), a member
of the fibrinogen superfamily. CD25+ T cells express 6-fold
higher FGL2 mRNA than do CD25 T cells. Recombinant FGL2
inhibits T cell proliferation in response to anti-CD3 and anti-
CD28 and alloantigen stimulation. Treg cells from Fgl2 /
mice are less effective at suppressing the proliferation of WT
T cells and a polyclonal anti-FGL2 completely blocked the640 Immunity 30, May 22, 2009 ª2009 Elsevier Inc.suppressive activity of Treg cells in a dose-dependent manner.
Recombinant FGL2 binds to DCs via the inhibitory FcgRIIB
receptor (Shalev et al., 2008). Treatment of DCs from wild-type
mice with FGL2 results in decreased expression of CD80 and
CD86, whereas FGL2 treatment had no inhibitory effect on
DCs from FcgRIIB-deficient mice. Thus, FGL2 may represent
an important Treg cell product that primarily downregulates DC
function.
Neuropilin (Nrp-1) has been proposed to play a role in the inter-
action of Treg cells with DCs. Nrp-1 is a receptor for class III sem-
aphorins and a coreceptor for vascular endothelial growth factor.
Nrp-1 is preferentially expressed on Treg cells and can be
induced by ectopic expression of Foxp3 in Foxp3 T cells (Sarris
et al., 2008). Nrp-1promotes long interactions betweenTregcells
and immatureDCs.BlockingofNrp-1decreases the frequencyof
long interactions,whereasectopic expression ofNrp-1 in Foxp3
T cells increases the number of long interactions. Anti-Nrp-1
completely abrogates suppression of proliferation mediated by
Treg cells when the responder T cells are stimulated with low
concentrations of antigen. These data suggest that the role of
Nrp-1 is to give Treg cells a head start over naive responder
T cells under conditions in which antigen is limiting.
The Pleiotropic Role of TGF-b in Treg Cell Development,
Homeostasis, and Effector Function
Although TGF-b plays a critical role in the induction of Foxp3+
Treg cell in vivo and in vitro (Chen et al., 2003; Liu et al., 2008)
and in Treg cell homeostasis (Marie et al., 2005), its role as
a suppressor effector molecule remains controversial. The
majority of studies with either human or mouse Treg cells have
failed to demonstrate that Treg cell function in vitro could be
reversed by anti-TGF-b. Nakamura et al. (2001) first raised the
possibility that TGF-b produced by Treg cells is bound to the
cell surface by an as yet uncharacterized receptor and would
mediate suppression in a cell contact-dependent fashion. In their
studies, TGF-b is detected on the surface of resting and activated
CD25+ T cells, and suppression could be reversed by high
concentrations of anti-TGF-b. They postulated that latent TGF-b,
bound to the cell surface of activated Treg cells, is delivered
directly to responder CD25 T cells and is then locally converted
to its active form. In contrast to these studies, Piccirillo et al.
(2002) were unable to show a requirement for either the produc-
tion of TGF-b or responsiveness to TGF-b in Treg cell-mediated
suppression. High concentrations of anti-TGF-b did not reverse
suppression, nor did anti-TGF-b or a soluble form of the TGF-
bRII inhibit suppression mediated by activated Treg cells.
More recent studies have re-evaluated the cell surface expres-
sion and function of TGF-b on both human and mouse Foxp3+
Treg cell. Neither active nor latent (TGF-b bound to latency asso-
ciated peptide [LAP]) TGF-b could bedetected on the cell surface
of resting human or mouse Foxp3+ Treg cells. However, after
activation via theTCR, a very highpercentage of activatedmouse
and human Treg cells could be stained with anti-LAP (and
presumably expressed latent TGF-b), whereas none were reac-
tive with anti-TGF-b (Andersson et al., 2008; Tran et al., 2009b).
Latent TGF-b is likely produced by the Treg cells, as indicated
by the fact that expression of LAP on activated Treg cells is in-
hibited by the addition of monensin to the activation cultures
and that treatment of Treg cells with an siRNA specific for
Immunity
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significance of the selective expression of latent TGF-b on both
activated human and mouse Treg cell? The simplest interpreta-
tion of this finding that would be consistent with the model
proposedbyNakamura et al. (2001)would be that the cell surface
latent TGF-b is activated and plays a major role in Treg cell
suppression by acting directly on responder T cells or on the
DCs. However, siRNA knock down of TGF-b in human Treg cells
resulted in only a slight reduction in their suppressor capacity
in vitro (D. Tran and E.M.S., unpublished data), and soluble re-
combinant LAP (the most potent neutralizer of TGF-b) had no
effect on the ability of activated mouse Treg cells to inhibit the
activation of naive T cells. We have recently demonstrated (An-
dersson et al., 2008) that themajor role of the expression of latent
TGF-b on the surface of murine Treg cells is to convert Foxp3
T cells into Foxp3+ Treg cells by a mechanism of infectious toler-
ancewhen both populations are activated via their TCRs in aDC-
independent manner. It is also possible that TGF-b on the cell
surface of activated Treg cells may be delivered to DCs and
downregulate their function.
The contribution of TGF-b to the suppressive capacity of Treg
cells in vivo has also been difficult to dissect. A number of in vivo
experiments have demonstrated that autocrine production of
TGF-b by Treg cells is not essential for Treg cell suppression
in vivo. For example, transfer of Tgfb1/ splenocytes to
Rag2/ mice induced disease with features similar to those of
the Tgfb1/ mice, disease transfer was accelerated by the
depletion of Tgfb1/ Treg cells, but cotransfer of Tgfb1/
Treg cells attenuated disease (Mamura et al., 2002). Although
TGF-b appears to play a nonredundant role in control of intestinal
inflammation, Treg cells from Tgfb1/ mice or from mice ex-
pressing a dominant-negative form of the TGF-bRII are capable
of inhibiting IBD induced by Foxp3 T cells in vivo (Fahlen et al.,
2005). Importantly, the function of Tgfb1/ Treg cells is abro-
gated by anti-TGF-b, indicating that TGF-b is absolutely required
for protection from IBD, but can be derived from a non-Treg cell
source. In contrast, mice with a T cell-specific deletion of TGF-
b production (Li et al., 2007) or processing (Pesu et al., 2008)
do develop an autoimmune syndrome including IBD. The differ-
ences between these studies are unclear, but may relate to the
flora in different animal colonies. It is also possible that Treg
cell-mediated Foxp3 induction may be required at sites of signif-
icant inflammation such as the gastrointestinal tract. TGF-bmay
also play a role in the development of Treg cells that are capable
of producing IL-10, as shown by the fact that treatment of mice
with anti-TGF-b prevented the conversion of CD4+Foxp3 T cells
to CD4+Foxp3+IL-10 producers in intestine-associated lymphoid
tissues (Maynard et al., 2007).
In Vivo Veritas: Mechanisms
of Treg Cell Suppression In Vivo
Although multiple mechanisms for Treg cell suppression have
been shown in vitro, it is unclear whether the same or different
mechanisms are used by Treg cells in vivo. Analysis of the poten-
tial mechanisms of Treg cell suppression in vivo is even more
complex. In contrast to the fixed environment of the culture
dish, in vivo the Treg cell must be able to home to various parts
of the body and to physically interact directly with effector T cells
or indirectly via the APCs. Put simply, there is ample room in vivofor the effector T cells to evade suppression by Treg cells. It is
unknown whether the suppressive activity of Treg cells is
executed in secondary lymphoid organs or at the site of inflam-
mation or both. There are also a number of major differences
between the properties of Treg cells in vivo compared to
in vitro. First, although Treg cells are nonresponsive or anergic
to stimulation via the TCR in vitro, Treg cells expand after
engagement of their TCR by cognate antigen in a manner indis-
tinguishable from conventional CD4+ T cells in vivo (Walker et al.,
2003). Second, as discussed above, most studies of Treg cell
suppression in vitro have failed to define a role for Treg cell-
produced suppressor cytokines such as IL-10, and the role of
TGF-b production by Treg cells remains controversial. However,
multiple studies in vivo have shown that secretion of IL-10 by
Treg cells constitutes an important component of their suppres-
sive effects (Belkaid, 2007; McGeachy et al., 2005). The major
effect of Treg cells on T cell activation in vitro is to inhibit priming
by blocking IL-2 production and effector cell expansion.
However, the contribution of IL-2 in the antigen-driven expan-
sion of CD4+ T cells in vivo remains unknown, as indicated by
the fact that antigen-specific T cells from Il2/mice expand nor-
mally after stimulation by antigen in vivo. A further confounding
factor in the analysis of Treg cell function in vivo is that many
of the studies on Treg cell suppression of autoimmunity have
been performed after transfer of Treg cells and effectors into
immunodeficient mice, an environment that promotes lympho-
penia-induced proliferation of either the Treg cells or the effec-
tors. The results of these studies may not be readily transferable
to studies performed in normal mice. Lastly, it remains unclear at
what stage of activation or differentiation effector T cells are
subject to Treg cell control.
The original studies documenting the ability of Foxp3+ T cells to
suppress autoimmune disease in vivo were all performed with
polyclonal populations of Treg cells. In vitro studies strongly
suggest that Treg cells have to be activated via their TCR to
suppress, so one question that remains to be addressed is
whether polyclonal Treg cells have to be activated via their TCR
to suppress in vivo? The source of the TCR signal during in vivo
activation of polyclonal Treg cells is not known. It is unlikely that
suppression is secondary to the presence of the very small
number of autoantigen-specific Treg cells present in the poly-
clonal population. A more likely scenario is that polyclonal Treg
cells are able to control various responses because they are
continuously being activated via their TCR by complexes of
MHC class II and ubiquitous self-peptides. Additional signals
(IL-2?) providedby the responding effector Tcellsmaybeneeded
to fully activate their suppressive activity in situ.
A detailed analysis of which components of the development
and activation of effector T cells are inhibited by polyclonal
Treg cells has not been performed. Kohm et al. (2002) supple-
mented normal mice with polyclonal Treg cells (potentially
doubling the number of Treg cells), immunized the mice with
an encephalitogenic peptide in adjuvant, and observed a down-
regulation of the severity of experimental autoimmune encepha-
lomyelitis (EAE). Suppression of disease was accompanied by
a decreased migration of cells into the target organ, but cytokine
production by effector T cells was not inhibited. In preliminary
studies with a similar model, we also failed to observe an inhibi-
tion of cytokine production, but did observe a markedImmunity 30, May 22, 2009 ª2009 Elsevier Inc. 641
Immunity
Reviewenhancement in the numbers of effectors cells in the draining
lymph node, raising the possibility that polyclonal Treg cells
might trap effector cells at the site of immunizaton and prevent
their egress to the target organ (T. Davidson and E.M.S., unpub-
lished data). In a model of autoimmune gastritis, when a small
numbers of autoreactive T cells were transferred into nude
mice expressing a tissue-specific autoantigen, polyclonal Treg
cells did not inhibit the migration of the autoreactive T cells into
the gastric lymph or into the target organ, nor did they inhibit
the antigen-driven expansion of autoreactive T cells in the gastric
lymph node. The polyclonal Treg cells appeared to block the
differentiation of the autoreactive T cells to Th1 effector cells (Di-
Paolo et al., 2005). Sarween et al. (2004) reported that polyclonal
Treg cells inhibited the development of diabetes induced by
transfer of OVA-specific transgenic T cells into Rag1/mice ex-
pressing OVA driven by the rat insulin promoter. They also
observed a minimal effect on the expansion of the transgenic
T cells in the draining lymph node accompanied by a reduction
in the amount of IFN-g production. In contrast to the studies
on gastritis, they did observe an inhibition of T cell infiltration
into the pancreatic islets.
Very few studies have dealt with the effectiveness of polyclonal
Treg cells in treating established autoimmune disease. One
advantage of the IBD model is that Treg cells can cure ongoing
colitis 4 weeks after initiation of disease (Uhlig et al., 2006).
Treg cells proliferate and accumulate in the mesenteric lymph
node and also in the colonic lamina propria. At both sites, the
progeny of the Treg cells are found to be in direct contact with
CD11c+ DCs as well as effector T cells. These findings suggest
that regulation of an active immune responsebyTreg cells occurs
in the draining lymph node as well as at the site of inflammation.
The majority of the Foxp3+ T cells were IL-10-secreting cells and
the IL-10-producing cells were selectively enriched in the colonic
lamina propria suggesting that the gut environment may condi-
tion the Treg cells to differentiate into IL-10-producing Treg cells
in the colon. It was impossible in this model to directly examine
the effects of theTregcells oneffector cell numbers or expansion.
Two studies have used two-photon laser scanning micros-
copy to examine potential interactions between antigen-specific
Treg cells and DCs in lymph nodes (Tang et al., 2006; Tadokoro
et al., 2006). In the absence of antigen-specific Treg cells, an
arrest of antigen-specific effector T cells interacting with DCs
was observed, whereas in the presence of Treg cells, the arrest
of effector T cells was markedly diminished. Treg cells were also
capable of suppressing the formation of stable clusters of diabe-
togenic TCR transgenic T cells in isolated pancreatic lymph no-
des. In both of these studies, the conventional T cells showed
diminished cytokine production in the lymph nodes. Importantly,
stable Treg cell-T effector cell interactions or simultaneous inter-
actions between Treg cell-T effector cell and the DCs were not
seen. Although one might conclude from these studies that
Treg cells exert their suppressive actions on DCs in secondary
lymphoid organs by diminishing the activation of the DCs, by in-
hibiting the ability of DCs to physically interact with effectors
cells, or by blocking the capacity of DCs to present antigen, no
direct effects of the Treg cells on DC function were seen in these
studies.
The majority of studies have shown that antigen-specific Treg
cells are more potent at suppressing the induction of autoim-642 Immunity 30, May 22, 2009 ª2009 Elsevier Inc.mune disease than polyclonal populations. Klein et al. (2003)
attempted to model the mechanisms by which antigen-specific
Treg cells inhibit effector T cell activation by cotransferring
antigen-specific Treg cells and naive T cells followed by priming
with antigen in incomplete adjuvant. Treg cells were stimulated
by antigen to proliferate almost as strongly as naive CD4+
T cells and a marked accumulation of Treg cells was observed
in antigen-draining lymph nodes. Both Treg and non-Treg cells
expanded in an antigen-dependent manner and produced
typical patterns of cytokines, the Treg IL-10 and the naive T cells
IL-2 and IFN-g. At later time points, effector cell expansion
ceased, but when the few effector cells remaining were restimu-
lated, they appeared to be fully competent producers of both
IL-2 and IFN-g. It was concluded from these studies that, in
contrast to the in vitro studies, no influence of Treg cells on the
differentiation of naive T cells could be observed; the responder
cells may have died or migrated from the draining nodes.
Very different conclusions were drawn from a study in which
antigen-specific TGF-b-induced Treg cells were used to prevent
gastritis (DiPaolo et al., 2007). The induced Treg cells were long
lived in vivo, maintained Foxp3 expression, and protected mice
from disease. The major effect of the Treg cells was to inhibit the
expansion of the cotransferred effector cells on day 5 after trans-
fer. Most importantly, DCs that had been exposed to Treg cells
in vivo had a reduced capacity to present the endogenous auto-
antigen compared to those from noninjected mice. It thus
appears that one mechanism by which Treg cells exert their
function in vivo is by reducing the ability of DCs to prime autor-
eactive T cells, hence stopping the autoimmune response before
it even starts. This study supports the experiments that demon-
strate that the presence of Treg cells results in fewer long-lasting
interactions between effector T cells and DCs, but also demon-
strates that theTregcells exert their negativeeffectsbydecreasing
the stimulatory capacity of DCs rather than by competing with
the effectors for antigen or by acting directly on the effector cells
to prevent their interaction with DCs.
In contrast to the effects of antigen-specific Treg cells on CD4+
effector T cells, Chen et al. (2005) have shown that antigen-
specific Treg cells do not inhibit the expansion of CD8+ effector
cells or their differentiation to cytotoxic T lymphocytes (CTLs),
but do block the ability of the activated CD8+ T cells to kill
antigen-expressing target cells. Impaired TGF-b signaling in
the CD8+ effectors conferred resistance to Treg cell-mediated
suppression of cytolytic ability in vivo. Further analysis of this
model (Mempel et al., 2006) by multiphoton microscopy demon-
strated that in the presence of Treg cells, the CTLs underwent
normal differentiation, migrated normally, and responded to
antigen-presenting target cells by forming stable conjugates.
Ex vivo analysis of CTLs show that their failure to kill target cells
in vivo is correlated with impaired release of lytic granules,
whereas cellular granule content is unchanged. Suppression is
reversible upon in vivo removal of Treg cells after CTL priming,
but did not require prolonged physical interaction of CTLs with
Treg cells. Thus, Treg cells can modulate a terminal effector
function of CD8+ T cells.
Taken together, these studies indicate that Treg cells can
suppress immune responses in vivo at multiple levels and that
distinct or even contradictory mechanisms may predominate in
different experimental models. A number of critical questions
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used by Treg cells in lymphoid versus nonlymphoid tissues?
What are the signals that direct Treg cell migration to nonlym-
phoid tissues? Do Treg cells need to reprogram their homing
and chemokine receptor profiles in order to enter nonlymphoid
sites? Is Treg cell suppression in nonlymphoid sites primarily
mediated by the production of anti-inflammatory cytokines,
whereas suppression in lymphoid sites is exclusively secondary
to inhibition of priming? Can polyclonal Treg cells migrate to sites
of autoantigen expression or are signals generated by activated
effector T cells required to recruit the polyclonal Treg cells? Do
polyclonal Treg cells also target DCs and suppress later steps
in the differentiation of pathogenic Th1 or Th17 cells by blocking
the production of IL-12 or IL-23 by DCs? Lastly, are the effects of
Treg cells in vivo reversible upon removal of the Treg cells as
suggested by a number of studies (Samy et al., 2005; Mempel
et al., 2006) or do Treg cells delete effectors or render them
permanently anergic?
Reversal of Suppression
Although themechanism of Treg cell-mediated inhibition of T cell
activation remains unknown, one approach to determining
potential cell surface antigens involved in this process has
been to reverse suppression with antibodies to candidate anti-
gens. One member of the tumor necrosis receptor superfamily
(TNFRSF), the GITR (TNFRSF18), has been claimed to play an
important role in regulation of T cell suppressor activity. Both
a polyclonal antiserum and a mAb to the GITR were initially re-
ported to reverse suppression mediated by freshly isolated
Treg cells (Shevach and Stephens, 2006). Because the GITR is
rapidly upregulated on Foxp3 T cells and Treg cells constitu-
tively express the GITR, it was impossible to conclude that the
anti-GITR mediated its effects by acting solely on the Treg cells.
When combinations of WT and Tnfrsf18/ Foxp3 T cells and
Treg cells were used in coculture experiments, ligation of the
GITR on the responders, not the Treg cells, was required to abro-
gate suppression. Thus, engagement of the GITR on effector
cells by its ligand on APC early during the course of an immune
response rendered the responder cells resistant to suppression
by Treg cells. This model is also compatible with the observa-
tions of Pasare and Medzhitov (2003) that soluble factors such
as IL-6 released by activated DCs can act directly on effector
cells, but not Treg cells, to render them resistant to suppression.
A second member of the TNF receptor superfamily, OX40
(CD137), is also constitutively expressed on mouse Treg cells
and transiently expressed on Foxp3 lymphocytes upon antigen
stimulation. It has been claimed that engagement of OX40
reverses the suppressive function of Treg cells by acting on
the Treg cells rather than by rendering the responder cells resis-
tant to suppression (Valzasina et al., 2005). If Treg cells are pre-
incubated with an agonist anti-OX40, they lose the ability to
suppress effector T cells in an in vivo mouse model of graft
versus host disease. Reversal of Treg cell suppression by anti-
OX40 also resulted in complete rejection of already established
tumors (Piconese et al., 2008). However, it is difficult to rule out
that persistence of the agonistic antibody also costimulated
effector T cells that expressed OX40 after activation. It remains
possible that engagement of OX40 in some manner abolishes
Treg cell suppression, but the effects of anti-OX40 in vivo couldalso be secondary to partial depletion of Treg cells by the anti-
body. Curiously, a recent study has demonstrated that Treg cells
can inhibit the release of allergic mediators from mast cells and
that inhibition was mediated by OX40 expressed on the Treg
cell interacting with OX40L expressed on the mast cells (Gri
et al., 2008). Thus, OX40 in some cases can function as a
suppressor effector molecule.
Engagement of Toll-like receptor 2 (TLR2) on Treg cells has
also been claimed to reverse the suppressive effects of mouse
Treg cells in some studies (Liu et al., 2006; Sutmuller et al.,
2006). In contrast, the suppressive function of human Treg cells
is enhancedby engagement of TLR5by its ligand, flagellin (Crellin
et al., 2005). The major problem with the interpretation of these
studies is that the TLR are also expressed at low amounts on
Foxp3 T cells and atmuch higher amounts onmultiple cell types
in the innate immune system. Contamination of the preparations
of Treg cells used in these studies by non-Treg cells may have
contributed to the discrepant results. The other major problem
with the interpretation of studies on reversal of suppression is
thatwehave very little understanding of the biochemical pathway
used by the Treg cells and even less understanding of the signals
inducedby those agents that are claimed to reverse suppression.
On the brighter side, it is clear that Treg cell-mediated suppres-
sion can be overcome by costimulation of effector cells (e.g.,
via the GITR or OX40). Reagents that stimulate these pathways
may be valuable adjuncts to enhance responses both to tumor
vaccines and responses to weak vaccines to infectious agents.Concluding Comments
The in vitro models of Treg cell function certainly suggest that
Treg cells may use multiple mechanisms to suppress immune
responses. Yet, how many of the mechanisms are actually oper-
ative in vivo? Have we now exhausted the list of potential
suppressor mechanisms or is a critical suppressor pathway yet
to be discovered? One argument against the existence of an
as yet to be discovered ‘‘major player’’ is that onewould have ex-
pected that a mutation in such a pathway would have led to the
development of a severe autoimmune syndrome similar to that
seen with mutations of Foxp3. A more important question is
whether our current understanding of Treg cell suppressor
mechanisms offers any insight into how Treg cell function can
be manipulated in vivo. For example, can we transiently and
selectively downregulate Treg cell function prior to the adminis-
tration of a tumor vaccine? Alternatively, how can we enhance
Treg cell numbers or effectiveness without inducing systemic
immunosuppression? Even if we can increase Treg cell numbers
by using cellular biotherapy with expanded polyclonal or
antigen-specific Treg cells to treat autoimmune disease, will
the expanded Treg cells survive in vivo? How often would such
therapy have to be administered? Will Treg cells induce long-
lasting antigen-specific tolerance via an infectious tolerance
mechanism? Some of these questions are likely only to be
answered by well-designed and well-controlled clinical trials.REFERENCES
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